Batten Disease Treatment Market with Top Major Players Like Seneb BioSciences, Inc., BioMarin Pharmaceuticals and ReGenX Biosciences LLC

Overview:

Batten disease, also known as Neuronal Ceroid Lipofuscinoses, is a rare, inherent, neurological disorder that begins in childhood but may take a few years to show symptoms. It is one of around 50 diseases that fall under the category of lysosome deficiency disorders, caused due to an abnormality of genes resulting in their inability to synthesize essential proteins. The disease usually appear around the age of 2 to10 years and characterized by malfunctioning of body. Early symptoms may show subtle changes in learning and behaviour, however over time, child may suffer from progressive loss of sight, mental impairment, speech and motor reactions, may lead to blindness dementia, worsening seizures, and finally death. It can be diagnosed with the help of brain scans, skin or tissue dampening, blood or urine tests, and imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT).

Get PDF Brochure Of This Report With Detailed Analysis @ https://www.coherentmarketinsights.com/insight/request-pdf/831

Drivers:

Increasing prevalence or incidence of batten disease across the globe is expected to augment the growth of the global batten disease treatment market over the forecast period. For instance, as reported by the U.S. Centres for Disease Control and Prevention (CDC), on average, Batten is observed in around 2-4 per 100,000 live births in the U.S. Though, it is rare, the prevalence of Batten disease is higher in some European countries, such as Sweden, Finland, and others, compared to rest of the world.

According to the Batten Disease Support and Research Association, more than one child in the same family often has Batten disease. Moreover, according to the article, The Daily News and Analysis, published in June 2016, in India, more than 20 million child suffer from rare diseases, which are expensive to treat. This in turn is expected to create lucrative growth opportunities for market players active in the market. Few clinical trials and studies would help reduce the disease outcome.

Restraints:

Lack of awareness among people and manufacturers, unavailability of the safe and effective treatment or inadequate treatment facilities are some major factors expected to hamper growth of the global batten disease treatment market.

Regional analysis:

North America and Europe are expected to witness a strong growth in the global batten disease treatment market due to increasing prevalence of batten disease in these regions. For instance, King’s College London, Texas Children’s Hospital, and Baylor College of Medicine jointly developed a treatment to improve the neural symptoms of juvenile batten disease in the mouse model. This has brought a ray of hope to patients and families suffering from Batten disease.

Key developments:

Research institutes are adopting strategies such as collaborations to develop dependable treatment choices for batten disease. For instance, Baylor College of Medicine, King’s College London and Texas Children’s Hospital collaborated and found a treatment to enhance neurological signs in the mouse with batten disease. Such research and discoveries are providing hopes to the patients suffering batten disease.

Buy This Research Study Report For Quick Access@ https://www.coherentmarketinsights.com/insight/buy-now/831

Key players:

Key players active in the global batten disease treatment market are Seneb BioSciences, Inc., ReGenX Biosciences LLC, and BioMarin Pharmaceuticals.

In 2017, the U.S. Food and Drug Administration (FDA) approved BioMarin Pharmaceuticals’ Brineura, a drug to treat batten disease.